<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605475</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885A2213</org_study_id>
    <nct_id>NCT00605475</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Multi Center, Randomized, Double Blind, Placebo-controlled, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered Intravenously to Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate, in patients with Type 2 Diabetes Mellitus, whether
      Canakinumab can lower Glycosylated hemoglobin / hemoglobin A1c (HbA1c) and/or peak glucose
      levels in response to an oral glucose tolerance test (OGTT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Plasma HbA1c (Glycosylated Hemoglobin / Hemoglobin A1c)</measure>
    <time_frame>Baseline, Day 28, Day 84, Day 126, End of Study (168 [+/- 5] days after dosing)</time_frame>
    <description>Blood was drawn after an overnight fast to measure plasma HbA1c levels. End of Study is defined as the last Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 - 4 Hours Following Oral Glucose Tolerance Test (OGTT )</measure>
    <time_frame>Baseline, Day 28, Day 84</time_frame>
    <description>Mean Change in Glucose level stimulated by OGTT. Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Glucose levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma C-peptide AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test (OGTT)</measure>
    <time_frame>Baseline, Day 28, Day 84</time_frame>
    <description>Blood samples were drawn after an overnight fast and standard OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. C-peptide levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Insulin AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test ( OGTT )</measure>
    <time_frame>Baseline, Day 28, Day 84</time_frame>
    <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Proinsulin AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test ( OGTT )</measure>
    <time_frame>Baseline, Day 28, Day 84</time_frame>
    <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Glucagon AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test</measure>
    <time_frame>Baseline, Day 28, Day 84</time_frame>
    <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Glucagon levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Peak Plasma Insulin/Proinsulin Level, Following Oral Glucose Tolerance Test (OGTT)</measure>
    <time_frame>Baseline, Day 28, Day 84</time_frame>
    <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin and proinsulin levels were measured. The insulin/proinsulin level was calculated by dividing the insulin level by the proinsulin level. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Insulin Secretion Rate ( ISR ) Relative to Glucose, 0 - 4 Hours</measure>
    <time_frame>Day 28, Day 84</time_frame>
    <description>Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Mean ISR relative to glucose over 0-4 hours was calculated as follows:
Mean ISR relative to glucose = mean ISR / (glucose AUC/time interval). The mean ISR was computed as an AUC (area under the curve) using the linear trapezoidal rule divided by the corresponding time interval. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Insulin Secretion Rate ( ISR ), 0 - 4 Hours</measure>
    <time_frame>Day 28, Day 84</time_frame>
    <description>Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. The mean ISR over 0 - 4 hours was computed as an AUC (area under the curve) using the linear trapezoidal rule divided by the corresponding time interval. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity Index ( ISI ) at Day 28, Day 48</measure>
    <time_frame>Day 28, Day 84</time_frame>
    <description>Insulin sensitivity index (ISI) = 10000 / [fasting insulin (μIU/mL) x fasting glucose (mg/dL) x mean 2 hour insulin(μIU/mL) x mean 2 hour glucose (mg/dL)]1/2 where mean 2 hour insulin (or glucose) was defined as the insulin (or glucose)AUC(0-2 hr) divided by the time period (2 hr). In normal subjects the mean score ± SE is 0.366 ± 0.029. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulinogenic Index, 0 - 30 Minutes</measure>
    <time_frame>Day 28, Day 84</time_frame>
    <description>Insulinogenic index (0-30 min)
[Change in insulin (0-30 min) (μIU/mL)] / [Change in glucose (0-30 min) (mg/dL)]
[insulin (μIU/mL) at 30 min - insulin (μIU/mL) at 0 min] / [glucose (mg/dL) at 30 min - glucose (mg/dL) at 0 min), where insulin (or glucose) at 0 min was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Peak Plasma Glucose Following Oral Glucose Tolerance Test ( OGTT )</measure>
    <time_frame>Baseline, Day 28, Day 84</time_frame>
    <description>Mean Change in Peak Glucose level stimulated by OGTT. Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Change from baseline assessed at Day 28 and 84. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Peak Plasma Fructosamine Level</measure>
    <time_frame>Baseline, Day 14, Day 28, Day 56, Day 84, Day 126, End of Study (168 [+/- 5] days after dosing)</time_frame>
    <description>Blood was drawn to measure change in plasma Fructosamine Level, from baseline to Day 14, 28, 56, 84, 126 and End of Study ( defined as the final available post-randomization assessment up to the last regularly scheduled visit at Day 168 [+/- 5]). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance as Measured by the Homeostatic Model Assessment (HOMA-IR)</measure>
    <time_frame>Baseline, Day 28, Day 84</time_frame>
    <description>Insulin Resistance is measured via the Homeostatic Model Assessment (HOMA-IR) using a computer to model insulin sensitivity. Insulin Sensitivity (HOMA-%S), where 100% is normal, is the reciprocal of insulin resistance (100/S%). HOMA IR = [fasting insulin (μU/mL)] x [fasting plasma glucose (mmol/L)] / 22.5 where fasting insulin (or glucose) was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>β-cell Function as Measured by the Homeostatic Model Assessment (HOMA-β )</measure>
    <time_frame>Baseline, Day 28, Day 84</time_frame>
    <description>β cell function is measured by the Homeostatic Model Assessment(HOMA-β) using a computer to model β cell function and insulin sensitivity . β cell function is related to Insulin Sensitivity (HOMA-%S) and is the reciprocal of insulin resistance (100/S%). HOMA β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) - 3.5] where fasting insulin (or glucose) was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Death, Serious Adverse Events (SAEs), Adverse Events (AE) Above 5% Frequency</measure>
    <time_frame>Baseline to End of Study (56[+/-2] and 168 [+/- 5] days after dosing for Cohort 1 and Cohorts 2-4, respectively)</time_frame>
    <description>An adverse event is any unwanted event, whether related to study drug or not occurring during the study period. A Serious Adverse Event (SAE) is an event resulting in death, requiring or prolonging hospitalization, a congenital anomaly or other important medical event. AEs and SAEs were recorded at each visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants were assigned to receive canakinumab in one of four cohorts; 1) Single IV infusion of canakinumab 0.3 mg/kg; 2) Singe IV infusion of canakinumab 10 mg/kg; 3) single IV infusion of canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of canakinumab 0.03 mg/kg.
All participants were required to take a concomitant stable daily dose of metformin during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible participants were assigned to receive placebo to canakinumab in one of four cohorts; 1) Single IV infusion of placebo to canakinumab 0.3 mg/kg; 2) Singe IV infusion of placebo to canakinumab 10 mg/kg; 3) single IV infusion of placebo to canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of placebo to canakinumab 0.03 mg/kg.
All participants were required to take a concomitant stable daily dose of metformin during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <description>Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.</description>
    <arm_group_label>Canakinumab</arm_group_label>
    <other_name>ACZ885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants continued on their stable daily dose of metformin throughout the study</description>
    <arm_group_label>Canakinumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Glumetza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged 18 to 70 years, with type 2 diabetes mellitus
             (non-insulin dependent diabetes) for at least 6 months prior to study start

          -  HbA1c between 7.0 and 9.5%

          -  On stable dose metformin monotherapy

          -  Stable body weight

        Exclusion Criteria:

          -  Poorly controlled type 2 diabetes (very low or very high blood sugar levels, or other
             indicators of poor control)

          -  Acute infections prior to dosing

          -  Patients with type 1 diabetes (insulin-dependent diabetes)

          -  Taking diabetes medication (other than metformin)

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NOVARTIS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Research Medical Testing</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Research International - Cetero Research Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Center Towson</name>
      <address>
        <city>MD</city>
        <state>Maryland</state>
        <zip>21286</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles River Clinical Services</name>
      <address>
        <city>NW Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Moenchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersberg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2008</study_first_posted>
  <results_first_submitted>September 1, 2011</results_first_submitted>
  <results_first_submitted_qc>January 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 13, 2012</results_first_posted>
  <last_update_submitted>January 10, 2012</last_update_submitted>
  <last_update_submitted_qc>January 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Canakinumab</keyword>
  <keyword>ACZ885</keyword>
  <keyword>IL-1B antagonist</keyword>
  <keyword>metformin</keyword>
  <keyword>glycemic control</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Canakinumab Infusion 0.3 mg/kg</title>
          <description>Single dose intravenous (IV) infusion of canakinumab 0.3 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Placebo to Canakinumab 0.3 mg/kg</title>
          <description>Single dose IV infusion of placebo to Canakinumab 0.3 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
          <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
          <description>Single dose IV infusion of Placebo to Canakinumab 10 mg/kg</description>
        </group>
        <group group_id="P5">
          <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
          <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
        </group>
        <group group_id="P6">
          <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
          <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
        </group>
        <group group_id="P7">
          <title>Cohort 3 : Canakinumab Infusion 1.5 mg/kg</title>
          <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
        </group>
        <group group_id="P8">
          <title>Cohort 3: Placebo Infusion</title>
          <description>Single dose IV infusion of Placebo</description>
        </group>
        <group group_id="P9">
          <title>Cohort 4 : Canakinumab Injection 0.03 mg/kg</title>
          <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
        </group>
        <group group_id="P10">
          <title>Cohort 4: Placebo to Canakinumab 0.03 mg/kg</title>
          <description>Single dose IV injection of Placebo to Canakinumab 0.03 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="24"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="22"/>
                <participants group_id="P7" count="22"/>
                <participants group_id="P8" count="24"/>
                <participants group_id="P9" count="18"/>
                <participants group_id="P10" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Abnormal Laboratory Values</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Canakinumab Infusion 0.3 mg/kg</title>
          <description>Single dose intravenous (IV) infusion of canakinumab 0.3 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1: Placebo to Canakinumab 0.3 mg/kg</title>
          <description>Single dose IV infusion of placebo to Canakinumab 0.3 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
          <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
          <description>Single dose IV infusion of Placebo to Canakinumab 10 mg/kg</description>
        </group>
        <group group_id="B5">
          <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
          <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
        </group>
        <group group_id="B6">
          <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
          <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
        </group>
        <group group_id="B7">
          <title>Cohort 3 : Canakinumab Infusion 1.5 mg/kg</title>
          <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
        </group>
        <group group_id="B8">
          <title>Cohort 3: Placebo Infusion</title>
          <description>Single dose IV infusion of Placebo</description>
        </group>
        <group group_id="B9">
          <title>Cohort 4 : Canakinumab Injection 0.03 mg/kg</title>
          <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
        </group>
        <group group_id="B10">
          <title>Cohort 4: Placebo to Canakinumab 0.03 mg/kg</title>
          <description>Single dose IV injection of Placebo to Canakinumab 0.03 mg/kg</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="45"/>
            <count group_id="B5" value="25"/>
            <count group_id="B6" value="24"/>
            <count group_id="B7" value="23"/>
            <count group_id="B8" value="24"/>
            <count group_id="B9" value="20"/>
            <count group_id="B10" value="10"/>
            <count group_id="B11" value="231"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="7.60"/>
                    <measurement group_id="B2" value="52" spread="6.96"/>
                    <measurement group_id="B3" value="57.1" spread="9.38"/>
                    <measurement group_id="B4" value="57.5" spread="7.95"/>
                    <measurement group_id="B5" value="53.9" spread="7.58"/>
                    <measurement group_id="B6" value="55" spread="8.45"/>
                    <measurement group_id="B7" value="55.1" spread="9.28"/>
                    <measurement group_id="B8" value="54.7" spread="6.41"/>
                    <measurement group_id="B9" value="53.9" spread="9.07"/>
                    <measurement group_id="B10" value="56" spread="8.67"/>
                    <measurement group_id="B11" value="54.6" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma C-peptide AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test (OGTT)</title>
        <description>Blood samples were drawn after an overnight fast and standard OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. C-peptide levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Baseline, Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4): Placebo Infusion</title>
            <description>Pooled Placebo of Cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma C-peptide AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test (OGTT)</title>
          <description>Blood samples were drawn after an overnight fast and standard OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. C-peptide levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>pmol*h/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 41, 41, 21, 23, 23, 31, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-335" spread="178.1"/>
                    <measurement group_id="O2" value="-614" spread="178.1"/>
                    <measurement group_id="O3" value="-492" spread="392.4"/>
                    <measurement group_id="O4" value="-25" spread="367.6"/>
                    <measurement group_id="O5" value="779" spread="367.6"/>
                    <measurement group_id="O6" value="129" spread="319.4"/>
                    <measurement group_id="O7" value="-553" spread="394.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 41, 43, 22, 24, 23, 32, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-601" spread="275.1"/>
                    <measurement group_id="O2" value="-205" spread="268.6"/>
                    <measurement group_id="O3" value="143" spread="386.5"/>
                    <measurement group_id="O4" value="143" spread="361.1"/>
                    <measurement group_id="O5" value="654" spread="368.9"/>
                    <measurement group_id="O6" value="240" spread="316.0"/>
                    <measurement group_id="O7" value="-939" spread="396.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Plasma HbA1c (Glycosylated Hemoglobin / Hemoglobin A1c)</title>
        <description>Blood was drawn after an overnight fast to measure plasma HbA1c levels. End of Study is defined as the last Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Baseline, Day 28, Day 84, Day 126, End of Study (168 [+/- 5] days after dosing)</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2:Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4): Placebo Infusion</title>
            <description>Pooled Placebo of Cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma HbA1c (Glycosylated Hemoglobin / Hemoglobin A1c)</title>
          <description>Blood was drawn after an overnight fast to measure plasma HbA1c levels. End of Study is defined as the last Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 45, 45, 25, 23, 23, 34, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.057"/>
                    <measurement group_id="O2" value="-0.26" spread="0.057"/>
                    <measurement group_id="O3" value="-0.25" spread="0.065"/>
                    <measurement group_id="O4" value="-0.30" spread="0.069"/>
                    <measurement group_id="O5" value="-0.47" spread="0.068"/>
                    <measurement group_id="O6" value="-0.24" spread="0.056"/>
                    <measurement group_id="O7" value="-0.13" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 44, 44, 25, 23, 23, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.102"/>
                    <measurement group_id="O2" value="-0.15" spread="0.105"/>
                    <measurement group_id="O3" value="-0.04" spread="0.118"/>
                    <measurement group_id="O4" value="-0.43" spread="0.124"/>
                    <measurement group_id="O5" value="-0.59" spread="0.124"/>
                    <measurement group_id="O6" value="0.32" spread="0.103"/>
                    <measurement group_id="O7" value="-0.15" spread="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 126 (n= 45, 45, 21, 22, 23, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.101"/>
                    <measurement group_id="O2" value="-0.02" spread="0.101"/>
                    <measurement group_id="O3" value="-0.08" spread="0.126"/>
                    <measurement group_id="O4" value="-0.22" spread="0.123"/>
                    <measurement group_id="O5" value="-0.40" spread="0.120"/>
                    <measurement group_id="O6" value="-0.19" spread="0.101"/>
                    <measurement group_id="O7" value="-0.11" spread="0.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n= 43, 45, 24, 20, 21, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.121"/>
                    <measurement group_id="O2" value="-0.01" spread="0.118"/>
                    <measurement group_id="O3" value="0.27" spread="0.162"/>
                    <measurement group_id="O4" value="-0.18" spread="0.178"/>
                    <measurement group_id="O5" value="-0.39" spread="0.173"/>
                    <measurement group_id="O6" value="-0.12" spread="0.138"/>
                    <measurement group_id="O7" value="0.32" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Insulin AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test ( OGTT )</title>
        <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Baseline, Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4): Placebo Infusion</title>
            <description>Pooled placebo from Cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Insulin AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test ( OGTT )</title>
          <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>µIU*h/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 43, 45, 18, 21,16, 29, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="6.156"/>
                    <measurement group_id="O2" value="-14.25" spread="6.017"/>
                    <measurement group_id="O3" value="-12.61" spread="8.173"/>
                    <measurement group_id="O4" value="6.06" spread="7.477"/>
                    <measurement group_id="O5" value="2.06" spread="8.494"/>
                    <measurement group_id="O6" value="-8.26" spread="6.421"/>
                    <measurement group_id="O7" value="-1.35" spread="7.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 43, 45, 22, 23, 19, 31, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.68" spread="11.054"/>
                    <measurement group_id="O2" value="-6.97" spread="10.805"/>
                    <measurement group_id="O3" value="-8.38" spread="9.095"/>
                    <measurement group_id="O4" value="2.44" spread="8.673"/>
                    <measurement group_id="O5" value="-6.65" spread="9.522"/>
                    <measurement group_id="O6" value="-4.09" spread="7.592"/>
                    <measurement group_id="O7" value="-10.52" spread="9.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Proinsulin AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test ( OGTT )</title>
        <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Baseline, Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4): Placebo Infusion</title>
            <description>Pooled placebo from cohort 3 and 4. ingle dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Proinsulin AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test ( OGTT )</title>
          <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>pmol*h/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 36, 37, 22, 24, 21, 30, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="8.37"/>
                    <measurement group_id="O2" value="11.0" spread="8.25"/>
                    <measurement group_id="O3" value="-13.7" spread="18.78"/>
                    <measurement group_id="O4" value="-15.0" spread="17.64"/>
                    <measurement group_id="O5" value="26.1" spread="18.81"/>
                    <measurement group_id="O6" value="-16.2" spread="16.38"/>
                    <measurement group_id="O7" value="-22.3" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 36, 37, 23, 24, 21, 30, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="10.95"/>
                    <measurement group_id="O2" value="7.8" spread="10.79"/>
                    <measurement group_id="O3" value="-25.8" spread="20.96"/>
                    <measurement group_id="O4" value="-9.3" spread="20.33"/>
                    <measurement group_id="O5" value="39.6" spread="21.68"/>
                    <measurement group_id="O6" value="-25.9" spread="18.76"/>
                    <measurement group_id="O7" value="-17.3" spread="22.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Glucagon AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test</title>
        <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Glucagon levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Baseline, Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4) Placebo Infusion</title>
            <description>Pooled placebo from cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Glucagon AUC ( Area Under the Curve) 0-4 Hours, Following Oral Glucose Tolerance Test</title>
          <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Glucagon levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>pmol*h/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 41, 44, 22, 23, 23, 34, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="2.30"/>
                    <measurement group_id="O2" value="-4.0" spread="2.22"/>
                    <measurement group_id="O3" value="-3.1" spread="3.43"/>
                    <measurement group_id="O4" value="-3.7" spread="3.37"/>
                    <measurement group_id="O5" value="-0.6" spread="3.36"/>
                    <measurement group_id="O6" value="-2.7" spread="2.78"/>
                    <measurement group_id="O7" value="-5.5" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 42, 45, 23, 23, 23, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="2.96"/>
                    <measurement group_id="O2" value="-2.0" spread="2.86"/>
                    <measurement group_id="O3" value="-1.0" spread="4.46"/>
                    <measurement group_id="O4" value="-1.8" spread="4.48"/>
                    <measurement group_id="O5" value="14.7" spread="4.46"/>
                    <measurement group_id="O6" value="2.9" spread="3.74"/>
                    <measurement group_id="O7" value="-4.0" spread="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 - 4 Hours Following Oral Glucose Tolerance Test (OGTT )</title>
        <description>Mean Change in Glucose level stimulated by OGTT. Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Glucose levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Baseline, Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3and 4): Placebo Infusion</title>
            <description>Pooled Placebo of Cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 - 4 Hours Following Oral Glucose Tolerance Test (OGTT )</title>
          <description>Mean Change in Glucose level stimulated by OGTT. Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Glucose levels over 4 hrs were shown as Area Under the Curve, (AUC). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>mmol*h/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="0.98"/>
                    <measurement group_id="O2" value="-0.9" spread="0.96"/>
                    <measurement group_id="O3" value="1.6" spread="1.66"/>
                    <measurement group_id="O4" value="-0.9" spread="1.65"/>
                    <measurement group_id="O5" value="-2.8" spread="1.73"/>
                    <measurement group_id="O6" value="-2.3" spread="1.41"/>
                    <measurement group_id="O7" value="-0.5" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.26"/>
                    <measurement group_id="O2" value="1.7" spread="1.24"/>
                    <measurement group_id="O3" value="2.6" spread="1.72"/>
                    <measurement group_id="O4" value="-2.8" spread="1.71"/>
                    <measurement group_id="O5" value="-1.2" spread="1.79"/>
                    <measurement group_id="O6" value="-2.8" spread="1.46"/>
                    <measurement group_id="O7" value="-2.5" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Peak Plasma Insulin/Proinsulin Level, Following Oral Glucose Tolerance Test (OGTT)</title>
        <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin and proinsulin levels were measured. The insulin/proinsulin level was calculated by dividing the insulin level by the proinsulin level. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Baseline, Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4): Placebo Infusion</title>
            <description>Pooled placebo from Cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4:Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Peak Plasma Insulin/Proinsulin Level, Following Oral Glucose Tolerance Test (OGTT)</title>
          <description>Blood samples were drawn after an overnight fast and OGTT at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin and proinsulin levels were measured. The insulin/proinsulin level was calculated by dividing the insulin level by the proinsulin level. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>pmol/pmol</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 43, 45, 24, 24, 23, 34,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.173" spread="0.3902"/>
                    <measurement group_id="O2" value="-1.035" spread="0.3814"/>
                    <measurement group_id="O3" value="0.160" spread="0.7996"/>
                    <measurement group_id="O4" value="1.039" spread="0.7996"/>
                    <measurement group_id="O5" value="0.293" spread="0.8169"/>
                    <measurement group_id="O6" value="-0.031" spread="0.6755"/>
                    <measurement group_id="O7" value="0.518" spread="0.8832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 44, 44, 25, 24, 23, 34, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.852" spread="0.4890"/>
                    <measurement group_id="O2" value="-0.688" spread="0.4890"/>
                    <measurement group_id="O3" value="-0.689" spread="0.7973"/>
                    <measurement group_id="O4" value="0.923" spread="0.8138"/>
                    <measurement group_id="O5" value="0.250" spread="0.8313"/>
                    <measurement group_id="O6" value="0.682" spread="0.6871"/>
                    <measurement group_id="O7" value="-0.046" spread="0.8991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Insulin Secretion Rate ( ISR ) Relative to Glucose, 0 - 4 Hours</title>
        <description>Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Mean ISR relative to glucose over 0-4 hours was calculated as follows:
Mean ISR relative to glucose = mean ISR / (glucose AUC/time interval). The mean ISR was computed as an AUC (area under the curve) using the linear trapezoidal rule divided by the corresponding time interval. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4) Placebo Infusion</title>
            <description>Pooled placebo from cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Insulin Secretion Rate ( ISR ) Relative to Glucose, 0 - 4 Hours</title>
          <description>Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Mean ISR relative to glucose over 0-4 hours was calculated as follows:
Mean ISR relative to glucose = mean ISR / (glucose AUC/time interval). The mean ISR was computed as an AUC (area under the curve) using the linear trapezoidal rule divided by the corresponding time interval. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>pmol/min/m^2/mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 41, 43, 23, 23, 22, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" spread="0.53"/>
                    <measurement group_id="O2" value="18.0" spread="0.52"/>
                    <measurement group_id="O3" value="14.5" spread="1.03"/>
                    <measurement group_id="O4" value="17.1" spread="1.03"/>
                    <measurement group_id="O5" value="19.1" spread="1.05"/>
                    <measurement group_id="O6" value="18.5" spread="0.86"/>
                    <measurement group_id="O7" value="16.1" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 42, 43, 24, 24, 22, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="1.00"/>
                    <measurement group_id="O2" value="19.0" spread="0.99"/>
                    <measurement group_id="O3" value="16.8" spread="1.13"/>
                    <measurement group_id="O4" value="18.4" spread="1.13"/>
                    <measurement group_id="O5" value="18.5" spread="1.18"/>
                    <measurement group_id="O6" value="18.9" spread="0.96"/>
                    <measurement group_id="O7" value="15.9" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Insulin Secretion Rate ( ISR ), 0 - 4 Hours</title>
        <description>Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. The mean ISR over 0 - 4 hours was computed as an AUC (area under the curve) using the linear trapezoidal rule divided by the corresponding time interval. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4) Placebo Infusion</title>
            <description>Pooled placebo from cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Insulin Secretion Rate ( ISR ), 0 - 4 Hours</title>
          <description>Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. The mean ISR over 0 - 4 hours was computed as an AUC (area under the curve) using the linear trapezoidal rule divided by the corresponding time interval. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>pmol/min/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 42, 43, 23, 23, 23, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" spread="6.4"/>
                    <measurement group_id="O2" value="246" spread="6.3"/>
                    <measurement group_id="O3" value="207" spread="13.1"/>
                    <measurement group_id="O4" value="231" spread="13.0"/>
                    <measurement group_id="O5" value="262" spread="13.0"/>
                    <measurement group_id="O6" value="234" spread="10.9"/>
                    <measurement group_id="O7" value="212" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 43, 43, 25, 24, 23, 34, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248" spread="9.3"/>
                    <measurement group_id="O2" value="259" spread="9.3"/>
                    <measurement group_id="O3" value="234" spread="12.6"/>
                    <measurement group_id="O4" value="234" spread="12.7"/>
                    <measurement group_id="O5" value="254" spread="13.0"/>
                    <measurement group_id="O6" value="239" spread="10.8"/>
                    <measurement group_id="O7" value="197" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity Index ( ISI ) at Day 28, Day 48</title>
        <description>Insulin sensitivity index (ISI) = 10000 / [fasting insulin (μIU/mL) x fasting glucose (mg/dL) x mean 2 hour insulin(μIU/mL) x mean 2 hour glucose (mg/dL)]1/2 where mean 2 hour insulin (or glucose) was defined as the insulin (or glucose)AUC(0-2 hr) divided by the time period (2 hr). In normal subjects the mean score ± SE is 0.366 ± 0.029. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.</description>
        <time_frame>Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4): Placebo Infusion</title>
            <description>Pooled placebo of cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity Index ( ISI ) at Day 28, Day 48</title>
          <description>Insulin sensitivity index (ISI) = 10000 / [fasting insulin (μIU/mL) x fasting glucose (mg/dL) x mean 2 hour insulin(μIU/mL) x mean 2 hour glucose (mg/dL)]1/2 where mean 2 hour insulin (or glucose) was defined as the insulin (or glucose)AUC(0-2 hr) divided by the time period (2 hr). In normal subjects the mean score ± SE is 0.366 ± 0.029. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 40, 40, 12, 17, 14, 22, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="0.049"/>
                    <measurement group_id="O2" value="2.63" spread="0.049"/>
                    <measurement group_id="O3" value="3.13" spread="0.093"/>
                    <measurement group_id="O4" value="2.96" spread="0.077"/>
                    <measurement group_id="O5" value="3.57" spread="0.083"/>
                    <measurement group_id="O6" value="3.77" spread="0.068"/>
                    <measurement group_id="O7" value="3.39" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 39, 43, 13, 20, 14, 27, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="0.043"/>
                    <measurement group_id="O2" value="2.80" spread="0.041"/>
                    <measurement group_id="O3" value="3.34" spread="0.109"/>
                    <measurement group_id="O4" value="3.04" spread="0.085"/>
                    <measurement group_id="O5" value="2.99" spread="0.101"/>
                    <measurement group_id="O6" value="3.63" spread="0.074"/>
                    <measurement group_id="O7" value="3.70" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulinogenic Index, 0 - 30 Minutes</title>
        <description>Insulinogenic index (0-30 min)
[Change in insulin (0-30 min) (μIU/mL)] / [Change in glucose (0-30 min) (mg/dL)]
[insulin (μIU/mL) at 30 min – insulin (μIU/mL) at 0 min] / [glucose (mg/dL) at 30 min – glucose (mg/dL) at 0 min), where insulin (or glucose) at 0 min was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data..</description>
        <time_frame>Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4): Placebo Infusion</title>
            <description>Pooled placebo from cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Insulinogenic Index, 0 - 30 Minutes</title>
          <description>Insulinogenic index (0-30 min)
[Change in insulin (0-30 min) (μIU/mL)] / [Change in glucose (0-30 min) (mg/dL)]
[insulin (μIU/mL) at 30 min – insulin (μIU/mL) at 0 min] / [glucose (mg/dL) at 30 min – glucose (mg/dL) at 0 min), where insulin (or glucose) at 0 min was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data..</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n=44, 44, 17, 23 17, 32, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.174" spread="0.0754"/>
                    <measurement group_id="O2" value="0.140" spread="0.0754"/>
                    <measurement group_id="O3" value="0.090" spread="0.1995"/>
                    <measurement group_id="O4" value="0.105" spread="0.1735"/>
                    <measurement group_id="O5" value="0.139" spread="0.1991"/>
                    <measurement group_id="O6" value="0.102" spread="0.1464"/>
                    <measurement group_id="O7" value="0.137" spread="0.1942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n=43, 44, 17, 24, 20, 31, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.157" spread="0.0987"/>
                    <measurement group_id="O2" value="0.134" spread="0.0976"/>
                    <measurement group_id="O3" value="0.092" spread="0.1928"/>
                    <measurement group_id="O4" value="0.098" spread="0.1651"/>
                    <measurement group_id="O5" value="0.111" spread="0.1777"/>
                    <measurement group_id="O6" value="0.124" spread="0.1445"/>
                    <measurement group_id="O7" value="0.121" spread="0.1937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Peak Plasma Glucose Following Oral Glucose Tolerance Test ( OGTT )</title>
        <description>Mean Change in Peak Glucose level stimulated by OGTT. Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Change from baseline assessed at Day 28 and 84. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Baseline, Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3:Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3:Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4) Placebo Infusion</title>
            <description>Pooled placebo from Cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4:Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Peak Plasma Glucose Following Oral Glucose Tolerance Test ( OGTT )</title>
          <description>Mean Change in Peak Glucose level stimulated by OGTT. Blood samples were taken at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes. Change from baseline assessed at Day 28 and 84. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.30"/>
                    <measurement group_id="O2" value="0.0" spread="0.30"/>
                    <measurement group_id="O3" value="0.2" spread="0.55"/>
                    <measurement group_id="O4" value="-0.2" spread="0.55"/>
                    <measurement group_id="O5" value="-0.8" spread="0.57"/>
                    <measurement group_id="O6" value="-1.0" spread="0.47"/>
                    <measurement group_id="O7" value="0.1" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.38"/>
                    <measurement group_id="O2" value="0.6" spread="0.37"/>
                    <measurement group_id="O3" value="0.2" spread="0.58"/>
                    <measurement group_id="O4" value="-0.7" spread="0.58"/>
                    <measurement group_id="O5" value="0.3" spread="0.60"/>
                    <measurement group_id="O6" value="-0.9" spread="0.50"/>
                    <measurement group_id="O7" value="-0.3" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Peak Plasma Fructosamine Level</title>
        <description>Blood was drawn to measure change in plasma Fructosamine Level, from baseline to Day 14, 28, 56, 84, 126 and End of Study ( defined as the final available post-randomization assessment up to the last regularly scheduled visit at Day 168 [+/- 5]). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
        <time_frame>Baseline, Day 14, Day 28, Day 56, Day 84, Day 126, End of Study (168 [+/- 5] days after dosing)</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Peak Plasma Fructosamine Level</title>
          <description>Blood was drawn to measure change in plasma Fructosamine Level, from baseline to Day 14, 28, 56, 84, 126 and End of Study ( defined as the final available post-randomization assessment up to the last regularly scheduled visit at Day 168 [+/- 5]). Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>µmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 (n= 44, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.0"/>
                    <measurement group_id="O2" value="-0.7" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n= 45, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="3.72"/>
                    <measurement group_id="O2" value="-13.9" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n= 43, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="4.88"/>
                    <measurement group_id="O2" value="-0.9" spread="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 44, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.6" spread="4.71"/>
                    <measurement group_id="O2" value="-12.1" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 126 (n= 45, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="4.84"/>
                    <measurement group_id="O2" value="-1.1" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n = 45, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="7.25"/>
                    <measurement group_id="O2" value="4.9" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Resistance as Measured by the Homeostatic Model Assessment (HOMA-IR)</title>
        <description>Insulin Resistance is measured via the Homeostatic Model Assessment (HOMA-IR) using a computer to model insulin sensitivity. Insulin Sensitivity (HOMA-%S), where 100% is normal, is the reciprocal of insulin resistance (100/S%). HOMA IR = [fasting insulin (μU/mL)] x [fasting plasma glucose (mmol/L)] / 22.5 where fasting insulin (or glucose) was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.</description>
        <time_frame>Baseline, Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4): Placebo Infusion</title>
            <description>Pooled placebo from Cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance as Measured by the Homeostatic Model Assessment (HOMA-IR)</title>
          <description>Insulin Resistance is measured via the Homeostatic Model Assessment (HOMA-IR) using a computer to model insulin sensitivity. Insulin Sensitivity (HOMA-%S), where 100% is normal, is the reciprocal of insulin resistance (100/S%). HOMA IR = [fasting insulin (μU/mL)] x [fasting plasma glucose (mmol/L)] / 22.5 where fasting insulin (or glucose) was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 44, 45, 24, 24, 22, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="0.059"/>
                    <measurement group_id="O2" value="3.74" spread="0.058"/>
                    <measurement group_id="O3" value="4.03" spread="0.092"/>
                    <measurement group_id="O4" value="3.34" spread="0.091"/>
                    <measurement group_id="O5" value="3.31" spread="0.095"/>
                    <measurement group_id="O6" value="3.25" spread="0.078"/>
                    <measurement group_id="O7" value="3.31" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 44, 45, 24, 24, 23, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="0.054"/>
                    <measurement group_id="O2" value="3.62" spread="0.053"/>
                    <measurement group_id="O3" value="3.87" spread="0.103"/>
                    <measurement group_id="O4" value="3.43" spread="0.101"/>
                    <measurement group_id="O5" value="4.09" spread="0.103"/>
                    <measurement group_id="O6" value="3.06" spread="0.087"/>
                    <measurement group_id="O7" value="2.94" spread="0.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>β-cell Function as Measured by the Homeostatic Model Assessment (HOMA-β )</title>
        <description>β cell function is measured by the Homeostatic Model Assessment(HOMA-β) using a computer to model β cell function and insulin sensitivity . β cell function is related to Insulin Sensitivity (HOMA-%S) and is the reciprocal of insulin resistance (100/S%). HOMA β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) – 3.5] where fasting insulin (or glucose) was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.</description>
        <time_frame>Baseline, Day 28, Day 84</time_frame>
        <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Pooled (Cohort 3 and 4) : Placebo Infusion</title>
            <description>Pooled placebo from cohort 3 and 4. Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4: Anakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>β-cell Function as Measured by the Homeostatic Model Assessment (HOMA-β )</title>
          <description>β cell function is measured by the Homeostatic Model Assessment(HOMA-β) using a computer to model β cell function and insulin sensitivity . β cell function is related to Insulin Sensitivity (HOMA-%S) and is the reciprocal of insulin resistance (100/S%). HOMA β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) – 3.5] where fasting insulin (or glucose) was defined as the arithmetic mean of the -15, -10 and 0 min pre-glucose load values. Analysis of covariance with treatment as a fixed effect and baseline as the covariate was performed on log transformed data.</description>
          <population>All randomized participants who received study drug were included in the intent to treat population (ITT). Last observation carried forward (LOCF) was used to impute missing values.</population>
          <units>percent β-cell Function</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 44, 45, 24, 24, 22, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" spread="0.05"/>
                    <measurement group_id="O2" value="35.9" spread="0.05"/>
                    <measurement group_id="O3" value="38.1" spread="0.10"/>
                    <measurement group_id="O4" value="38.2" spread="0.10"/>
                    <measurement group_id="O5" value="42.0" spread="0.11"/>
                    <measurement group_id="O6" value="37.9" spread="0.09"/>
                    <measurement group_id="O7" value="38.3" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 44, 45, 24, 24, 23, 33, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" spread="0.06"/>
                    <measurement group_id="O2" value="34.3" spread="0.06"/>
                    <measurement group_id="O3" value="34.6" spread="0.10"/>
                    <measurement group_id="O4" value="37.6" spread="0.10"/>
                    <measurement group_id="O5" value="43.3" spread="0.10"/>
                    <measurement group_id="O6" value="37.2" spread="0.09"/>
                    <measurement group_id="O7" value="33.7" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Death, Serious Adverse Events (SAEs), Adverse Events (AE) Above 5% Frequency</title>
        <description>An adverse event is any unwanted event, whether related to study drug or not occurring during the study period. A Serious Adverse Event (SAE) is an event resulting in death, requiring or prolonging hospitalization, a congenital anomaly or other important medical event. AEs and SAEs were recorded at each visit.</description>
        <time_frame>Baseline to End of Study (56[+/-2] and 168 [+/- 5] days after dosing for Cohort 1 and Cohorts 2-4, respectively)</time_frame>
        <population>All randomized participants who received study medication were included in the Safety Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose intravenous (IV) infusion of canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Placebo to Canakinumab 0.3 mg/kg</title>
            <description>Single dose IV infusion of placebo to Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
            <description>Single dose IV infusion of Placebo to Canakinumab 10 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
            <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
            <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3 : Canakinumab Infusion 1.5 mg/kg</title>
            <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo Infusion</title>
            <description>Single dose IV infusion of Placebo</description>
          </group>
          <group group_id="O9">
            <title>Cohort 4 : Canakinumab Injection 0.03 mg/kg</title>
            <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
          </group>
          <group group_id="O10">
            <title>Cohort 4: Placebo to Canakinumab 0.03 mg/kg</title>
            <description>Single dose IV injection of Placebo to Canakinumab 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Death, Serious Adverse Events (SAEs), Adverse Events (AE) Above 5% Frequency</title>
          <description>An adverse event is any unwanted event, whether related to study drug or not occurring during the study period. A Serious Adverse Event (SAE) is an event resulting in death, requiring or prolonging hospitalization, a congenital anomaly or other important medical event. AEs and SAEs were recorded at each visit.</description>
          <population>All randomized participants who received study medication were included in the Safety Analysis</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events Above 5 % Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Canakinumab Infusion 0.3 mg/kg</title>
          <description>Single dose intravenous (IV) infusion of canakinumab 0.3 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1: Placebo to Canakinumab 0.3 mg/kg</title>
          <description>Single dose IV infusion of placebo to Canakinumab 0.3 mg/kg</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2: Canakinumab Infusion 10 mg/kg</title>
          <description>Single dose IV infusion of Canakinumab 10 mg/kg</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2: Placebo to Canakinumab 10 mg/kg</title>
          <description>Single dose IV infusion of Placebo to Canakinumab 10 mg/kg</description>
        </group>
        <group group_id="E5">
          <title>Cohort 3: Canakinumab Infusion 0.1 mg/kg</title>
          <description>Single dose IV infusion Canakinumab 0.1 mg/kg</description>
        </group>
        <group group_id="E6">
          <title>Cohort 3: Canakinumab Infusion 0.3 mg/kg</title>
          <description>Single dose IV infusion of Canakinumab 0.3 mg/kg</description>
        </group>
        <group group_id="E7">
          <title>Cohort 3 : Canakinumab Infusion 1.5 mg/kg</title>
          <description>Single dose IV infusion of canakinumab 1.5 mg/kg</description>
        </group>
        <group group_id="E8">
          <title>Cohort 3: Placebo Infusion</title>
          <description>Single dose IV infusion of Placebo</description>
        </group>
        <group group_id="E9">
          <title>Cohort 4 : Canakinumab Injection 0.03 mg/kg</title>
          <description>Single dose IV injection of Canakinumab 0.03 mg/kg</description>
        </group>
        <group group_id="E10">
          <title>Cohort 4: Placebo to Canakinumab 0.03 mg/kg</title>
          <description>Single dose IV injection of Placebo to Canakinumab 0.03 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary, however, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data ( i.e., data from all sites ) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778 8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

